Neoadjuvant chemotherapy for primary breast cancer: Lessons learned and opportunities to optimize therapy

被引：10

作者：

Esserman, L ^{[1
]}

机构：

[1] Univ Calif San Francisco, Ctr Med, Carol Franc Buck Breast Care Ctr, Dept Surg & Radiol, San Francisco, CA 94115 USA

来源：

ANNALS OF SURGICAL ONCOLOGY | 2004年 / 11卷 / 01期

关键词：

D O I：

10.1007/BF02524789

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3S / 8S

页数：6

共 67 条

[1]

Abraham DC, 1996, CANCER, V78, P91, DOI 10.1002/(SICI)1097-0142(19960701)78:1<91::AID-CNCR14>3.0.CO

[2]

2-2

[3] The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Brown, A ;

Smith, R ;

Mamounas, EP ;

Fisher, B ;

Margolese, R ;

Theoret, H ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174

[4] PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE [J].

BONADONNA, G ;

VERONESI, U ;

BRAMBILLA, C ;

FERRARI, L ;

LUINI, A ;

GRECO, M ;

BARTOLI, C ;

DEYOLDI, GC ;

ZUCALI, R ;

RILKE, F ;

ANDREOLA, S ;

SILVESTRINI, R ;

DIFRONZO, G ;

VALAGUSSA, P .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) :1539-1545

[5] Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? [J].

Bonnefoi, H ;

Diebold-Berger, S ;

Therasse, P ;

Hamilton, A ;

van de Vijver, M ;

MacGrogan, G ;

Shepherd, L ;

Amaral, N ;

Duval, C ;

Drijkoningen, R ;

Larsimont, D ;

Piccart, M .

ANNALS OF ONCOLOGY, 2003, 14 (03) :406-413

[6]

BRADBEER JW, 1985, REV ENDOCRINE RELA S, V16, P39

[7] Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation [J].

Buchholz, TA ;

Tucker, SL ;

Masullo, L ;

Kuerer, HM ;

Erwin, J ;

Salas, J ;

Frye, D ;

Strom, EA ;

McNeese, MD ;

Perkins, G ;

Katz, A ;

Singletary, SE ;

Hunt, KK ;

Buzdar, AU ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :17-23

[8] Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer [J].

Buzdar, AU ;

Singletary, SE ;

Theriault, RL ;

Booser, DJ ;

Valero, V ;

Ibrahim, N ;

Smith, TL ;

Asmar, L ;

Frye, D ;

Manuel, N ;

Kau, SW ;

McNeese, M ;

Strom, E ;

Hunt, K ;

Ames, F ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3412-3417

[9]

CAMPBELL FC, 1984, CLIN ONCOL, V10, P111

[10] Extending the indications for breast-conserving treatment to patients with locally advanced breast cancer [J].

Clark, J ;

Rosenman, J ;

Cance, W ;

Halle, J ;

Graham, M .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (02) :345-350

← 1 2 3 4 5 6 7 →